에 대한 최신 뉴스 McKesson (NYSE:MCK) 주식

McKesson

McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Large Cap

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

Federal Reserve

Markets

Movers

ETFs

$BTC

AAPL

AMZN

EPAM

GOOG

GOOGL

MSFT

MTCH

NVDA

SMCI

TSLA

VTRS

미국 주식 시장은 목요일(7일) 연준이 예상대로 금리 인하를 결정하고, 제롬 파월 연준 의장이  도널드 트럼프 당선 이후 사임 또는 해임 가능성을 일축하며 시장을 안심시킨 기자회견 이후 사상 최고치로 마감했다.

파월 연설 후 미국 증시 사상 최고치, &#39;매그니피센트 세븐&#39; 총 시가총액 17조 달러 돌파

Technicals

Trading Ideas

최고의 트레이더들은 주요 가격 수준과 주식 모멘텀에 집중하며, 지지선에서 과매도된 주식이 종종 반등하는 경향이 있음을 이해한다.

오늘의 주식: 맥케슨이 바닥을 찾았고 반등할 수 있을까?

News

ABNB

DELL

MNST

SBAC

SRPT

TECH

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 맥케슨 코퍼레이션(NYSE:MCK)의 주가는 예상보다 나쁜 FY25 1분기 매출 실적을 보고한 후 12.06% 하락했다. 분석가들은 회사의 목표 주가를 수정했다.

워너 브라더스 및 맥케슨은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 4일-8월 10일)

McKesson Corp

MALLINCKRODT PB LTD CO by Mallinckrodt plc.

Mallinckrodt PLC

Jade Leader Corp

McKesson Europe AG ADR

<a href="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/" title="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/">https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/</a>

Biotech

General

VRTX

InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And β-Thalassemia

Citigroup analyst Daniel Grosslight maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Buy and raises the price target from $630 to $713.

Price Target

Analyst Ratings

Citigroup Maintains Buy on McKesson, Raises Price Target to $713

<a href="https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts" title="https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts">https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts</a>

MDRX

ORCL

Reported November 10, 2024 'McKesson And Oracle Are Among The Final Bidders Vying To Acquire EMR Data Company Veradigm' - Axios

The U.S. stock market closed at record highs Thursday after the Federal Reserve's widely expected decision to lower interest rates and Fed Chair Jerome Powell's press conference where he reassured markets by dismissing concerns about his potential resignation or removal following the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">election of Donald Trump. </a>
The S&amp;P 500 — as tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — closed at 5,973 points, up 0.7% for the day.
Tech stocks outperformed the broader market, with the Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), surging 1.5% higher to an all-time high of 21,100 points.
Notably, the combined market capitalization of the Magnificent Seven — Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — soared to over $17 trillion, setting a new peak.
The Dow Jones stalled after Wednesday&#8217;s 3.6% rise, while small caps eased 0.4% following a 5.8% jump the previous day.
Top-performing sectors in the S&amp;P 500 were technology, up 1.8%, followed by communications services and consumer discretionary, both up by 1.3%. Financials, which rallied the most Wednesday, lagged on Thursday, down 1.5%.
<h3 class="wp-block-heading">Fed Cuts Rates, Powell Dismisses Concerns Over His Future </h3>
The Federal Reserve cut interest rates by 0.25% to 4.5%-4.75% as expected, a reduction in the pace of easing after the larger 0.5% cut in September.
The Fed recognized robust economic momentum, with the GDP rising by 2.8% in the second quarter, and resilient consumer confidence.
Powell downplayed weak October employment data, noting that near-zero job growth was largely due to temporary factors like strikes and hurricanes rather than underlying economic weakness.
Powell described the rate cut as part of a "further recalibration" of monetary policy, which he emphasized remains "restrictive." He hinted at the possibility of more easing in the future but refrained from signaling a specific rate cut at the December meeting, stressing a data-dependent approach.
When asked if he would resign if requested by Trump, Powell responded firmly, "No," reiterating that the president does not have the legal authority to remove the Fed chair.
Following Powell's comments, market-implied expectations for a 25-basis-point rate cut in December surged to 75%, recovering from Wednesday's post-election dip.
Treasury yields pulled back sharply, with the 10-year yield dropping 10 basis points to 4.33%, almost erasing the spike from the previous day.
The U.S. dollar weakened 0.7%, while gold prices, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), rebounded 1.8% after Wednesday&#8217;s 3% slump. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded up by 1% at 4:30 p.m. in New York, hitting a record-high of $76,990 during the session. 
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Thursday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg %</td>
</tr>
<tr>
<td>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)</td>
<td>233.00</td>
<td>14.95%</td>
</tr>
<tr>
<td>Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</td>
<td>13.20</td>
<td>13.69%</td>
</tr>
<tr>
<td>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>25.47</td>
<td>12.21%</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>9.38</td>
<td>11.91%</td>
</tr>
<tr>
<td>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)</td>
<td>607.76</td>
<td>10.64%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Losers On Thursday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>)</td>
<td>31.11</td>
<td>-17.86%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.93</td>
<td>-11.34%</td>
</tr>
<tr>
<td>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>57.09</td>
<td>-7.33%</td>
</tr>
<tr>
<td>Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>)</td>
<td>277.22</td>
<td>-5.71%</td>
</tr>
<tr>
<td>Becton, Dickinson and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>227.16</td>
<td>-5.38%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41824236/feds-interest-rate-cut-pace-expected-to-slow-economists-weigh-trumps-white-house-re">Fed&#8217;s Interest Rate Cut Pace Expected To Slow: Economists Weigh Trump&#8217;s White House Return</a></li>
</ul>
Wall Street bull illustration created using artificial intelligence via MidJourney.

Wall Street Hits Record Highs After Powell's Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading

After Wednesday&#8217;s &#8220;everything rally&#8221; spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting.
The Fed is widely expected to cut interest rates by 25 basis points, bringing them to a range of 4.5%-4.75%, following a previous 50-basis-point cut in September.
Yet, all eyes are on Fed Chair Jerome Powell&#8217;s comments at 2:30 p.m. ET regarding the potential for future rate hikes and his views on inflation risks. Concerns from the market center on the possibility of a policy U-turn driven by higher fiscal deficits and price pressures from trade tariffs under a Trump administration.
Tech stocks led gains, with the Nasdaq 100 extending its record-breaking levels, surpassing 21,000 points and eyeing a third consecutive positive session. The S&amp;P 500 and Dow Jones posted more modest gains, while the Russell 2000 paused after Wednesday&#8217;s 5.8% leap.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remained a top performer among mega-cap stocks, bolstered by expectations of Elon Musk&#8216;s influence in the upcoming administration.
Treasury yields reversed a substantial portion of Wednesday's post-election increase, while the U.S. dollar dipped by 0.7%.
Metal commodities rebounded after Wednesday&#8217;s sharp losses, with gold rising 1.3%, silver up 2% and copper rallying over 4%.
Oil prices strengthened by 1%, with West Texas Intermediate trading around $72 per barrel.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 0.8%, reaching $76,000 to extend its record highs, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) outperformed with a gain of over 4%.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,050.78</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,968.27</td>
<td>0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,748.20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.10</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.7% to $594.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;stalled at $437.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.3% to $512.38.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.3% to $236.67.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, rising 1.3%. The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Some relevant reactions to earnings reports are:
<ul>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), up 0.1%, </li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), up 6.2%, </li>
<li>MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), down 16%, </li>
<li>APPLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), up 43%, </li>
<li>McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), up 11%, </li>
<li>Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), up 6.3%, </li>
<li>Transdigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>), down 4.4%</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
This image was created using artificial intelligence.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Macro Economic Events

Sector ETFs

Commodities

Tech

$ETH

SPDR Dow Jones Industrial Average ETF Trust

GILD

MELI

QCOM

TTWO

XLRE

Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?

Investors with a lot of money to spend have taken a bullish stance on McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for McKesson.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 36%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $204,282, and 7 are calls, for a total amount of $211,877.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $340.0 to $610.0 for McKesson over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for McKesson's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across McKesson's significant trades, within a strike price range of $340.0 to $610.0, over the past month.
<h3>McKesson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730997923_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.8</td>
<td>$14.0</td>
<td>$14.5</td>
<td>$520.00</td>
<td>$75.4K</td>
<td align="right">32</td>
<td align="right">83</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$16.9</td>
<td>$13.7</td>
<td>$14.0</td>
<td>$520.00</td>
<td>$56.0K</td>
<td align="right">32</td>
<td align="right">123</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.8</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$520.00</td>
<td>$44.9K</td>
<td align="right">32</td>
<td align="right">31</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$187.0</td>
<td>$178.0</td>
<td>$181.93</td>
<td>$450.00</td>
<td>$36.3K</td>
<td align="right">46</td>
<td align="right">2</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$37.3</td>
<td>$32.1</td>
<td>$34.0</td>
<td>$565.00</td>
<td>$33.9K</td>
<td align="right">159</td>
<td align="right">124</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Following our analysis of the options activities associated with McKesson, we pivot to a closer look at the company's own performance.
<h3>McKesson's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,075,384, the MCK's price is up by 10.26%, now at $605.65. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On McKesson</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $684.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Baird has upgraded their rating to Outperform and adjusted the price target to $688. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on McKesson, which currently sits at a price target of $680. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for McKesson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on McKesson: Analyzing the Surge in Options Activity

U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Thursday.
Shares of HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results and issued FY24 <a href="https://www.benzinga.com/news/earnings/24/11/41790530/hubspot-shares-climb-after-strong-q3-results-eps-beat-revenues-beat">guidance above estimates</a>.
HubSpot reported quarterly earnings of $2.22 per share, which beat the analyst consensus estimate of $1.91. Quarterly revenue clocked in at $669.7 million which beat the analyst consensus estimate of $646.9 million and is an increase over sales of $557.55 million from the same period last year.
HubSpot shares jumped 7.9% to $645.11 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares jumped 47% to $247.63 after the company reported better-than-expected third-quarter financial results.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) surged 39% to $48.57 following third-quarter earnings.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 34.8% to $12.40 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) gained 32.8% to $25.07 following third-quarter results.</li>
<li>Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) gained 32.7% to $11.61 after the company reported better-than-expected quarterly EPS and sales.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 28.2% to $18.46 after the company reported better-than-expected quarterly financial results.</li>
<li>Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) jumped 26.2% to $16.51 following upbeat quarterly results.</li>
<li>Wolverine World Wide, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) jumped 26.2% to $20.25 following strong quarterly results.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) gained 22.4% to $68.66 after the company reported better-than-expected quarterly financial results.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) rose 21.4% to $19.98 following third-quarter results.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) gained 20.9% to $34.56 following better-than-expected quarterly earnings.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 17% to $8.32 following upbeat earnings.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) rose 16% to $120.80 following stronger-than-expected quarterly earnings.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) gained 15.5% to $29.20 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) gained 15.3% to $27.81 after reporting upbeat quarterly results.</li>
<li>Warner Bros. Discovery, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>) surged 14.7% to $9.61 following third-quarter earnings.</li>
<li>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) gained 13.7% to $230.60 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) rose 10.4% to $606.61 as the company reported better-than-expected second-quarter financial results.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 9.7% to $16.95.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 6.6% to $67.46.</li>
<li>Arm Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NYSE">ARM</a>) gained 5.4% to $152.43 following second-quarter results.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp">Jim Cramer Recommends Buying This Utilities Stock, Says No To XP</a></li>
</ul>

Intraday Update

BROS

CWAN

FARO

FRSH

HUBS

IONQ

LYFT

MBLY

HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/MCK/earnings">results on Wednesday</a>.
McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per share. The company reported quarterly sales of $93.70 billion which beat the analyst consensus estimate of $89.33 billion.
McKesson shares gained 4.6% to close at $549.31 on Wednesday.
These analysts made changes to their price targets on McKesson following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded McKesson from Neutral to Outperform and raised the price target from $531 to $688.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ece538c4a1e100001de8a1a/elizabeth-anderson">Evercore ISI Group analyst Elizabeth Anderson </a>maintained McKesson with an Outperform rating and raised the price target from $560 to $680.</li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-1024x557.png" alt="" class="wp-image-635361" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp">Jim Cramer Recommends Buying This Utilities Stock, Says No To XP</a></li>
</ul>

Earnings

These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings

Evercore ISI Group analyst Elizabeth Anderson maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Outperform and raises the price target from $560 to $680.

Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $680

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) price target from $271 to $351. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Duolingo shares closed at $318.85 on Wednesday. See how other analysts view this stock.</li>
<li>B of A Securities cut the price target for Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) from $8 to $7. B of A Securities analyst Julien Dumoulin-Smith maintained an Underperform rating. Bloom Energy shares closed at $10.97 on Wednesday. <a href="https://www.benzinga.com/quote/BE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Vertex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) from $45 to $60. Needham analyst Joshua Reilly maintained a Buy rating. Vertex shares closed at $49.76 on Wednesday. <a href="https://www.benzinga.com/quote/VERX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $531 to $688. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. McKesson shares settled at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) price target from $47 to $53. TD Cowen analyst Andrew Charles maintained a Buy rating. Dutch Bros shares closed at $34.94 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities cut Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) price target from $49 to $43. Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold. Devon Energy shares closed at $40.02 on Wednesday. <a href="https://www.benzinga.com/quote/DVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to Overweight. Sarepta shares settled at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners raised Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) price target from $10 to $25. Leerink Partners analyst Andrew Berens upgraded the stock from Market Perform to Outperform. Zymeworks shares closed at $15.61 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital slashed the price target for Crocs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NYSE">CROX</a>) from $150 to $110. Loop Capital analyst Laura Champine downgraded the stock from Buy to Hold. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods increased Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) price target from $18 to $21. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith downgraded the stock from Market Perform to Underperform. Lemonade shares closed at $29.29 on Wednesday. <a href="https://www.benzinga.com/quote/LMND/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

CROX

DUOL

LMND

VERX

ZYME

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for Sinclair, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Upgrades

SBGI

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

WIIM

McKesson shares are trading higher after the company reported better-than-expected Q2 financial results.

Baird analyst Eric Coldwell upgrades McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raises the price target from $531 to $688.

Baird Upgrades McKesson to Outperform, Raises Price Target to $688

Guidance

CORRECTION: McKesson Raises FY25 Adj EPS From $31.75-$32.55 To $32.40-$33.00 Vs $31.99 Est.

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 by 2.76 percent. The company reported quarterly sales of $93.70 billion which beat the analyst consensus estimate of $89.33 billion by 4.89 percent. This is a 21.35 percent increase over sales of $77.22 billion the same period last year.

Earnings Beats

McKesson Q2 2025 Adj EPS $7.07 Beats $6.88 Estimate, Sales $93.70B Beat $89.33B Estimate

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 20 years by 7.25% on an annualized basis producing an average annual return of 15.46%. Currently, McKesson has a market capitalization of $68.44 billion. 
Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 20 years ago, it would be worth $17,831.98 today based on a price of $527.67 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730748630_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $18,000 Today

Investors with a lot of money to spend have taken a bullish stance on McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for McKesson.
This isn't normal.
The overall sentiment of these big-money traders is split between 65% bullish and 35%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $538,721, and 12 are calls, for a total amount of $842,156.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $450.0 to $520.0 for McKesson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for McKesson options trades today is 166.17 with a total volume of 3,049.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for McKesson's big money trades within a strike price range of $450.0 to $520.0 over the last 30 days.
<h3>McKesson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730315752_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$13.8</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$510.00</td>
<td>$253.1K</td>
<td style="text-align: right;">763</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$12.8</td>
<td>$12.0</td>
<td>$12.7</td>
<td>$507.50</td>
<td>$158.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.8</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$450.00</td>
<td>$106.5K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.9</td>
<td>$12.9</td>
<td>$14.7</td>
<td>$450.00</td>
<td>$94.0K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">136</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.7</td>
<td>$14.3</td>
<td>$14.6</td>
<td>$450.00</td>
<td>$87.6K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">196</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
In light of the recent options history for McKesson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of McKesson</h3>
<ul>
<li>Currently trading with a volume of 455,253, the MCK's price is up by 0.02%, now at $499.28. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 7 days.</li>
</ul>
<h3>What Analysts Are Saying About McKesson</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $630.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Leerink Partners persists with their Outperform rating on McKesson, maintaining a target price of $630. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McKesson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About McKesson

McKesson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) short percent of float has fallen 12.43% since its last report. The company recently reported that it has 2.10 million shares sold short, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>McKesson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730226618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for McKesson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing McKesson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, McKesson's peer group average for short interest as a percentage of float is 5.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About McKesson?

<a href="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/ontada-collaborates-with-microsoft-to-transform-unstructured-oncology-data-with-azure-openai-technology/" title="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/ontada-collaborates-with-microsoft-to-transform-unstructured-oncology-data-with-azure-openai-technology/">https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/ontada-collaborates-with-microsoft-to-transform-unstructured-oncology-data-with-azure-openai-technology/</a>

'Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology' - McKesson

Veradigm And The 2025 M&A Boom

The health-tech industry's long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term growth. Keep reading... The integration of the latest technologies in the healthcare sector is continuously transforming its operations and contributing to its significant growth. The market is further poised for growth as it leverages the latest advancements like artificial intelligence (AI) and cloud computing.
Amid this backdrop, investors could consider investing in currently undervalued health-tech stocks McKesson Corporation (<a href="https://stocknews.com/stock/MCK/">MCK</a>), Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>), and Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>) for long-term growth.
Technology is all pervasive, be it healthcare devices, pharmaceuticals, processes, or services; advanced technologies are marking strong strides and revolutionizing how activities have been performed traditionally. Also, amid rising chronic illnesses, an aging population, and a growing demand for personalized medicine, the healthcare industry's reliance on digital technology is expected to increase further.
The healthcare technology market is gaining rapid pace with recent trends like AI, cloud computing, and cutting-edge digital devices and technologies. The market is poised to exhibit growth at a notable <a href="https://www.thebusinessresearchcompany.com/report/healthcare-technology-global-market-report#:~:text=Healthcare%20Technology%20Market%20Size%202024,(CAGR)%20of%2018.0%25.">CAGR of 18.7%</a>, resulting in a market volume of $1.03 trillion by 2028, driven by a focus on preventive healthcare, remote patient monitoring, and healthcare infrastructure development.
In specific, adoption of Artificial Intelligence (AI) has emerged as the strongest and transformative force, pushing the healthcare sector to new advances. AI technology is presenting credible solutions for current drawbacks with its advantages like precision, efficiency, lower costs, and enhanced patient care.
The global AI in healthcare market is projected to <a href="https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html">reach $148.40 billion by 2029</a>, growing at a CAGR of 48.1%. The growth in the market is driven by the need for improved computing power, reduced healthcare costs, and the rising partnerships and collaborations among the healthcare market players.
Considering the conducive industry trends, let's delve deeper into the fundamentals of currently undervalued health-tech stocks such as MCK, CAH, and ZBH for long-term growth.
McKesson Corporation (<a href="https://stocknews.com/stock/MCK/">MCK</a>)
MCK is an international provider of healthcare services. The company operates in four segments: U.S. Pharmaceutical; Prescription Technology Solutions (RxTS); Medical-Surgical Solutions; and International. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.
On September 5, MCK signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. The sale is part of MCK's enterprise strategy, enabling it to further focus and prioritize investments to grow its oncology and biopharma services platforms.
On August 26, MCK signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC, a business and administrative services organization, a leading physician-owned community oncology practice.
MCK purchased its controlling interest for approximately $2.49 billion in cash, which will represent approximately 70% ownership. The strategic acquisition marks an important step towards advancing community-based oncology care and enhances MCK's integrated oncology platform, Florida Cancer Specialists &amp; Research Institute, to join the US oncology network.
MCK's forward <a href="https://www.investopedia.com/terms/p/price-to-salesratio.asp">Price/Sales</a> of 0.22x is 94.5% lower than the industry average of 3.94x. Likewise, the stock's forward EV/EBIT multiple of 14.89 is 13% lower than the industry average of 17.11. Similarly, its forward non-GAAP P/E of 18.78x is 12.4% lower than the industry average of 21.44x.
During the second quarter that ended on September 30, 2024, MCK's revenues increased 21.3% year-over-year to $93.65 billion, and its adjusted gross profit increased 6.6% year-over-year to $3.25 billion. The company's adjusted earnings grew 8.8% from the year-ago value to $915 million, while its adjusted EPS came in at $7.07, up 13.5% year-over-year.
Street expects MCK's revenue and EPS for the third quarter (ending December 2024) to increase 18.5% and 9.4% year-over-year to $95.86 billion and $8.47, respectively. Moreover, the company topped the consensus EPS estimates in three of the trailing four quarters.
MCK's stock has increased 21.3% over the past month and 30.8% over the past year to close the last trading session at $615.59.
MCK's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Sentiment. Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, MCK is ranked #10 out of 64 stocks.
<a href="https://stocknews.com/stock/MCK/">Click here</a> to access additional ratings of MCK for Momentum, Quality, and Stability.
Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>)
CAH operates as a healthcare services and products company internationally. It offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It operates in Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution segments.
On November 11, CAH entered into definitive agreements to acquire two companies to accelerate CAH's strategic growth areas and enhance patient care. This includes the acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate the multi-specialty growth strategy.
The acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, will also improve CAH's at-home Solutions growth strategy.
On October 29, CAH opened its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business, which is nearly 317,000 square feet in size and will be available in early 2025. The facility provides modernized operations, expanded capacity, and specialized handling capabilities for products with strict storage requirements to healthcare customers.
In terms of forward non-GAAP P/E, CAH's 15.43x is 27.7% lower than the 21.33x industry average. Its 10.15x forward EV/EBITDA is 25.9% lower than the 13.69x industry average. Also, the company's forward Price/Sales of 0.13x is significantly lower than the 3.93x industry average.
CAH reported revenue of $52.28 billion for the first quarter that ended September 30, 2024. Its non-GAAP operating earnings grew 12.2% from the year-ago value to $625 million. The company's non-GAAP net earnings attributable to CAH came in at $460 million or $1.88 per common share, up 7% and 9.3% from the prior year's quarter, respectively.
The company raised its fiscal 2025 guidance range for non-GAAP EPS attributable to CAH to $7.75 to $7.90 from the previous range of $7.55 to $7.70. It also includes an update to the company's Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
Street expects CAH's EPS for the third quarter (ending March 2025) to increase 5.4% year-over-year to $2.19, and its EPS for the same quarter is expected to be $53.74 billion. Also, the company has topped the consensus EPS estimate in all four trailing quarters, which is remarkable.
Shares of CAH have surged 24.1% over the past six months and 15.9% over the past year to close the last trading session at $121.64.
CAH's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CAH has a B grade for Value. The stock is ranked #16 among the 64 stocks in the Medical - Services industry.
In addition to the POWR Ratings we've stated above, we also have CAH ratings for Sentiment, Momentum, Quality, Growth, and Stability. Get all CAH ratings <a href="https://stocknews.com/stock/CAH/">here</a>.
Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. The company designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products and S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products.
On August 7, ZBH entered into an agreement to acquire OrthoGrid Systems, Inc., a privately held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. The strategic acquisition aligns well with ZBH's operations and will help it address the challenges of orthopedic problems with innovative technology solutions.
In terms of forward Price/Book, ZBH's 1.66x is 43.1% lower than the 2.92x industry average. Its forward EV/EBITDA of 10.66x is 22% lower than the industry average of 13.66x. Also, the company's forward Price/Sales of 2.84x is 28% lower than the 3.94x industry average.
During the third quarter of 2024, which ended September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. Its adjusted operating profit rose 3.5% from the year-ago value to $480.20 million. Adjusted net earnings of ZBH and EPS came in at $353.20 million and $1.74, up 1.9% and 5.5% year-over-year, respectively.
Furthermore, the company's free cash flow rose 64.3% from the prior year's quarter to $310 million.
As per the company's updated guidance for fiscal 2024, ZBH projects reported revenue change between 3.5% - 4%. It also expects adjusted EPS in the range of $7.95 to $8.05.
Analysts expect ZBH's revenue for the fourth quarter (ending December 2024) to grow 3.9% year-over-year to $2.02 billion and its EPS for the same period is expected to increase 4.3% year-over-year to $2.30. Furthermore, the company surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
ZBH's shares have gained 3.5% over the past year to close the last trading session at $109.46.
ZBH's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value and Growth. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ZBH is ranked #18 out of 137 stocks.
In addition to the POWR Ratings we've stated above, we also have ZBH ratings for Stability, Momentum, Quality, and Sentiment. Get all ZBH ratings <a href="https://stocknews.com/stock/ZBH/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
&nbsp;

<hr />
MCK shares were unchanged in after-hours trading Tuesday. Year-to-date, MCK has gained 34.03%, versus a 26.77% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/mck-cah-zbh-3-undervalued-health-tech-stocks-to-buy-for-long-term-growth/>3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth

Analysts have been eager to weigh in on the Healthcare sector with new ratings on McKesson (MCK – Research Report), Fate Therapeutics (FATE – Resea...

Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)

McKesson, Cencora slapped with $266M in damages in Baltimore opioid lawsuit

Stephen Mandel's Lone Pine Capital disclosed las night in an SEC filing its holdings as of September 30, 2024. The fund's new buys during the third...

Lone Pine takes new positions in Salesforce and Starbucks, exits Mastercard

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

High Alpha stocks that are rated 'overweight' – MS

Jefferies analyst Brian Tanquilut maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $715.00. The company'...

Comments

McKesson

뉴스

에 대한 최신 뉴스 McKesson (NYSE:MCK) 주식

목요일, 11월 07, 2024

화요일, 9월 24, 2024

일요일, 8월 11, 2024

수요일, 8월 07, 2024

화요일, 5월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌